KCNQ3 activation by the naturally occurring phenol, eugenol.

Area of Science:

• Neuroscience
• Pharmacology
• Molecular Biology

Background:

• Ion channels, particularly the KCNQ family, are key targets for pain management by controlling neuronal excitability.
• Eugenol possesses analgesic properties and enhances the efficacy of diclofenac in pain models.
• The interaction of eugenol with ion channels involved in pain signaling requires further elucidation.

Purpose of the Study:

• To investigate the effects of eugenol on KCNQ ion channels and their role in pain modulation.
• To explore the molecular mechanisms underlying eugenol's interaction with KCNQ2/3 and TRPV1 channels.
• To assess the combined effects of eugenol and diclofenac on neuronal depolarization.

Main Methods:

• Electrophysiological recordings to study KCNQ2/3 and TRPV1 channel activity.
• Molecular docking simulations and mutagenesis experiments to identify eugenol's binding site.
• Co-expression of KCNQ2/3 and TRPV1 channels to evaluate combined drug effects.

Main Results:

• Eugenol acts as a KCNQ2/3 activator, shifting voltage dependence negatively, primarily via KCNQ3.
• Molecular modeling indicates eugenol binds to the voltage-sensing domain of KCNQ2/3 channels.
• Eugenol weakly activates TRPV1 but inhibits capsaicin- and acid-induced currents; diclofenac also inhibits TRPV1.
• In co-expressed cells, eugenol and diclofenac reduce membrane depolarization.

Conclusions:

• Eugenol's activation of KCNQ2/3 channels represents a novel mechanism for its analgesic effects.
• Eugenol modulates both KCNQ and TRPV1 channels, contributing to its pain-relieving properties.
• The findings support eugenol as a multi-target therapeutic agent for acute pain management.